The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases
Open accessAbstract
BACKGROUND: Brain metastases represent a significant healthcare problem. It is estimated that 20% to 40% of patients with cancer will develop metastatic cancer to the brain during the course of their illness. The burden of brain metastases impacts on quality and length of survival. Presenting symptoms include headache (49%), focal weakness (30%), mental disturbances (32%), gait ataxia (21%), seizures (18%), speech difficulty (12%), visual disturbance (6%), sensory disturbance (6%) and limb ataxia (6%).Brain metastases may spread from any primary site. The most common primary site is the lung, followed by the breast then gastrointestinal sites. Eighty-five per cent of brain metastases are found in the cerebral hemispheres, 10% to 15% in the cerebellum and 1% to 3% in the brainstem. Brain radiotherapy is used to treat cancer participants who have brain metastases from various primary malignancies.This is an update to the original review published in Issue 3, 2006. OBJECTIVES: To assess the effectiveness and adverse effects of whole brain radiotherapy (WBRT) in adult participants with multiple metastases to the brain. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 3, 2011), MEDLINE and EMBASE to July 2011. SELECTION CRITERIA: Randomized controlled trials (RCTs) comparing WBRT either alone or with other treatments in adults with newly diagnosed multiple metastases to the brain from any primary cancer. Trials of prophylactic WBRT were excluded as well as trials that dealt with surgery or WBRT, or both, for the treatment of single brain metastasis. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trial quality and abstracted information. Adverse effects information was also collected from the trials. MAIN RESULTS: Nine RCTs involving 1420 participants were added in this updated review. This updated review now includes a total of 39 trials involving 10,835 participants.Eight published reports (nine RCTs) showed no benefit of altered dose-fractionation schedules as compared to the control fractionation (3000 cGy in 10 fractions daily) of WBRT for overall survival. These studies also showed no improvement in symptom control nor neurologic improvement among the different dose-fractionation schemes as compared to 3000 cGy in 10 daily fractions of WBRT. This updated review includes two trials comparing 4000 cGy in 20 fractions given twice daily versus 2000 cGy in 4 or 5 daily fractions. Overall, there was no survival advantage (hazard ratio (HR) 1.18, 95% confidence interval (CI) 0.89 to 1.56, P = 0.25) with the use of 4000 cGy in 20 fractions given twice daily compared to 2000 cGy in 4 or 5 daily fractions.The addition of radiosensitizers in six RCTs did not confer additional benefit to WBRT in either the overall survival times (HR 1.08, 95% CI 0.98 to 1.18, P = 0.11) or brain tumour response rates (HR 0.87, 95% CI 0.60 to 1.26, P = 0.46).Two RCTs found no benefit in overall survival (HR 0.61, 95% CI 0.27 to 1.39, P = 0.24) with the use of WBRT and radiosurgery boost as compared to WBRT alone for selected participants with multiple brain metastases (up to four brain metastases). Overall, there was a statistically significant improvement in local brain control (HR 0.35, 95% CI 0.20 to 0.61, P = 0.0003) favouring the WBRT and radiosurgery boost arm. Only one trial of radiosurgery boost with WBRT reported an improved Karnofsky performance score outcome and improved ability to reduce the dexamethasone dose.In this updated review, a total of three RCTs reported on selected patients (with up to three or four brain metastases) treated with radiosurgery alone versus WBRT and radiosurgery. Based on two trials, there was no difference in overall survival (HR 0.98, 95% CI 0.71 to 1.35, P = 0.88). The addition of WBRT when added to radiosurgery significantly improved locally treated brain metasatases control (HR 2.61, 95% CI 1.68 to 4.06, P < 0.0001) and distant brain control (HR 2.15, 95% CI 1.55 to 2.99, P < 0.00001). On the other hand, one trial concluded that patients treated with WBRT and radiosurgery boost were significantly more likely to show a decline in learning and memory function as compared to those treated with radiosurgery alone.One RCT examined the use of WBRT and prednisone versus prednisone alone and produced inconclusive results. AUTHORS' CONCLUSIONS: None of the RCTs with altered WBRT dose-fractionation schemes as compared to standard (3000 cGy in 10 daily fractions or 2000 cGy in 4 or 5 daily fractions) found a benefit in terms of overall survival, neurologic function, or symptom control.The use of radiosensitizers or chemotherapy in conjunction with WBRT remains experimental.Radiosurgery boost with WBRT may improve local disease control in selected participants as compared to WBRT alone, although survival remains unchanged for participants with multiple brain metastases.This updated review now includes a total of three RCTs examining the
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J. P. T., Green, S. R., & Higgins, J. P. T. (2008) · Cited by 7,175
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
Radiobiology for the Radiologist.
(1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-3-438_1 · Cited by 3,484
Gaspar, L., Scott, C., Rotman, M., Asbell, S., Phillips, T., Wasserman, T., McKenna, W. G., & Byhardt, R. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)00619-0 · Cited by 2,544
Chang, E. L., Wefel, J. S., Hess, K. R., Allen, P. K., Lang, F. F., Kornguth, D. G., Arbuckle, R. B., Swint, J. M., Shiu, A. S., Maor, M. H., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70263-3 · Cited by 2,475
Andrews, D. W., Scott, C. B., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., Schell, M. C., Werner-Wasik, M., Demas, W., Ryu, J., Bahary, J.-P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16250-8 · Cited by 2,417
Aoyama, H., Shirato, H., Tago, M., Nakagawa, K., Toyoda, T., Hatano, K., Kenjyo, M., Oya, N., Hirota, S., Shioura, H., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2483 · Cited by 2,213
Kocher, M., Soffietti, R., Abacioglu, U., Villà, S., Fauchon, F., Baumert, B. G., Fariselli, L., Tzuk-Shina, T., Kortmann, R.-D., Carrie, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1655 · Cited by 1,988
Sperduto, P. W., Kased, N., Roberge, D., Xu, Z., Shanley, R., Luo, X., Sneed, P. K., Chao, S. T., Weil, R. J., Suh, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0527 · Cited by 1,425
Brown, P. D., Pugh, S., Laack, N. N., Wefel, J. S., Khuntia, D., Meyers, C., Choucair, A., Fox, S., Suh, J. H., Roberge, D., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not114 · Cited by 958
Borgelt, B., Gelber, R., Kramer, S., Brady, L. W., Chang, C. H., Davis, L. W., Perez, C. A., & Hendrickson, F. R. (1980) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(80)90195-9 · Cited by 953
Cancer principles and practice of oncology
Kerin, M. J. (1997) · Surgical Oncology · doi:10.1016/s0960-7404(97)90012-8 · Cited by 739
Incorporating variations in the quality of individual randomized trials into meta-analysis
Detsky, A. S., Naylor, C. D., O'Rourke, K., McGeer, A. J., & L'Abbé, K. A. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90085-2 · Cited by 640
Intracerebral metastases in solid-tumor patients: Natural history and results of treatment
Zimm, S., Wampler, G. L., Stablein, D., Hazra, T., & Young, H. F. (1981) · Cancer · doi:10.1002/1097-0142(19810715)48:2<384::aid-cncr2820480227>3.0.co;2-8 · Cited by 601
Meyers, C. A., Smith, J. A., Bezjak, A., Mehta, M. P., Liebmann, J., Illidge, T., Kunkler, I., Caudrelier, J.-M., Eisenberg, P. D., Meerwaldt, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.128 · Cited by 585
Radiobiology for the Radiologist
Malamud, H. (1995) · Clinical Nuclear Medicine · doi:10.1097/00003072-199501000-00029 · Cited by 546
Epidemiology of brain tumors: The national survey of intracranial neoplasms
Walker, A. E., Robins, M., & Weinfeld, F. D. (1985) · Neurology · doi:10.1212/wnl.35.2.219 · Cited by 487
Mehta, M. P., Rodrigus, P., Terhaard, C. H. J., Rao, A., Suh, J., Roa, W., Souhami, L., Bezjak, A., Leibenhaut, M., Komaki, R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.122 · Cited by 463
Neurologic Complications of Cancer
Wen, P. Y., & Glantz, M. J. (2003) · Neurologic Clinics · doi:10.1016/s0733-8619(02)00100-7 · Cited by 361
Kurtz, J. M., Gelber, R., Brady, L. W., Carella, R. J., & Cooper, J. S. (1981) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(81)90005-5 · Cited by 331
Murray, K. J., Scott, C., Greenberg, H. M., Emami, B., Seider, M., Vora, N. L., Olson, C., Whitton, A., Movsas, B., & Curran, W. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)00341-6 · Cited by 314
Roentgen-ray therapy of cerebral metastases
Chao, J.-H., Phillips, R., & Nickson, J. J. (1954) · Cancer · doi:10.1002/1097-0142(195407)7:4<682::aid-cncr2820070409>3.0.co;2-s · Cited by 282
Sperduto, P. W., Wang, M., Robins, H. I., Schell, M. C., Werner-Wasik, M., Komaki, R., Souhami, L., Buyyounouski, M. K., Khuntia, D., Demas, W., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.11.042 · Cited by 274
Management of central nervous system metastases
Lee, S.-H., Park, K.-J., Park, D.-H., Lee, J.-B., Kang, S.-H., Cho, T.-H., Park, J.-Y., Jung, Y.-G., & Hur, J. (2020) · Journal of Neurointensive Care · doi:10.32587/jnic.2020.00262 · Cited by 272
Robinet, G., Thomas, P., Breton, J. L., Léna, H., Gouva, S., Dabouis, G., Bennouna, J., Souquet, P. J., Balmes, P., Thiberville, L., et al. (2001) · Annals of Oncology · doi:10.1023/a:1008338312647 · Cited by 264
Quality of life 3: Rheumatoid arthritis
Riel, P. L. C. M., & Lankveld, W. G. J. M. (1993) · Pharmacy World & Science · doi:10.1007/bf02113936 · Cited by 251
Tsao, M., Xu, W., & Sahgal, A. (2012) · Cancer · doi:10.1002/cncr.26515 · Cited by 242
Self-citationT.Komarnicky, L., Phillips, T. L., Martz, K., Asbell, S., Isaacson, S., & Urtasun, R. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90137-s · Cited by 237
Regine, W. F., Scott, C., Murray, K., et al. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01676-5 · Cited by 209
Patil, C. G., Pricola, K., Sarmiento, J. M., Garg, S. K., Bryant, A., & Black, K. L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006121.pub4 · Cited by 205
Phase III Study of Efaproxiral As an Adjunct to Whole-Brain Radiation Therapy for Brain Metastases
Suh, J. H., Stea, B., Nabid, A., Kresl, J. J., Fortin, A., Mercier, J.-P., Senzer, N., Chang, E. L., Boyd, A. P., Cagnoni, P. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.1768 · Cited by 195
Phillips, T. L., Scott, C. B., Leibel, S. A., Rotman, M., & Weigensberg, I. J. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)00168-x · Cited by 185
Sperduto, P. W., Shanley, R., Luo, X., Andrews, D., Werner-Wasik, M., Valicenti, R., Bahary, J.-P., Souhami, L., Won, M., & Mehta, M. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.07.002 · Cited by 173
Priestman, T. J., Dunn, J., Brada, M., Rampling, R., & Baker, P. G. (1996) · Clinical Oncology · doi:10.1016/s0936-6555(05)80717-4 · Cited by 171
Neurologic Complications of Cancer
O'Neill, B. P. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.319-a · Cited by 166
Mehta, M. P., Shapiro, W. R., Phan, S. C., Gervais, R., Carrie, C., Chabot, P., Patchell, R. A., Glantz, M. J., Recht, L., Langer, C., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.05.068 · Cited by 164
Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases
Dziadziuszko, R., Ardizzoni, A., Postmus, P. E., Smit, E. F., Price, A., Debruyne, C., LeGrand, C. C., & Giaccone, G. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00234-x · Cited by 108
Lee, D. H., Han, J., Kim, H. T., Yoon, S. J., Pyo, H. R., Cho, K. H., Shin, S., Yoo, H., Lee, S. H., & Lee, J. S. (2008) · Cancer · doi:10.1002/cncr.23526 · Cited by 101
Guerrieri, M., Wong, K., Ryan, G. F., Millward, M. J., Quong, G., & Ball, D. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.02.019 · Cited by 100
Hart, M. G., Walker, M., Dickinson, H. O., & Grant, R. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003292.pub2 · Cited by 99
Neuhaus, T., Ko, Y., Müller, R.-P., Grabenbauer, G. G., Hedde, J.-P., Schueller, H., Köcher, M., Stier, S., & Fietkau, R. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604835 · Cited by 99
Chemotherapy of brain metastases from lung carcinoma
Ushio, Y., Arita, N., Hayakawa, T., et al. (1991) · Neurosurgery · doi:10.1097/00006123-199102000-00005 · Cited by 98
Knisely, J. P. S., Berkey, B. A., Chakravarti, A., Yung, A. W. K., Curran, W. J., Robins, H. I., Movsas, B., Brachman, D. G., Henderson, R. H., & Mehta, M. P. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.09.016 · Cited by 93
Chemotherapy of Brain Metastases from Lung Carcinoma: A Controlled Randomized Study
Ushio, Y., Arita, N., Hayakawa, T., et al. (1991) · Neurosurgery · doi:10.1227/00006123-199102000-00005 · Cited by 91
The combined use of radiation therapy and lonidamine in the treatment of brain metastases
DeAngelis, L., Currie, V. E., Kim, J. H., et al. (1989) · Journal of Neuro-Oncology · doi:10.1007/bf00172917 · Cited by 80
Scott, C., Suh, J. H., Stea, B., Nabid, A., & Hackman, J. (2007) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3180653c0d · Cited by 75
Eyre, H., Ohlsen, J., Frank, J., et al. (1984) · Journal of Neuro-Oncology · doi:10.1007/bf00178115 · Cited by 61
Supportive care for patients with gastrointestinal cancer
Ahmed, N., Ahmedzai, S. H., Vora, V., Harrison, S., & Paz, S. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003445.pub2 · Cited by 52
Non-invasive interventions for improving well-being and quality of life in patients with lung cancer
Solà, I., Thompson, E., Subirana‐Casacuberta, M., López, C., & Pascual, A. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004282.pub2 · Cited by 44
Cited by
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Peters, S., Adjei, A. A., Gridelli, C., Reck, M., Kerr, K., & Felip, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds226 · Cited by 930
Mulvenna, P., Nankivell, M., Barton, R., Faivre-Finn, C., Wilson, P., McColl, E., Moore, B., Brisbane, I., Ardron, D., Holt, T., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30825-x · Cited by 711
Reck, M., Popat, S., Reinmuth, N., De Ruysscher, D., Kerr, K. M., & Peters, S. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu199 · Cited by 679
Metadata
- Authors
- Tsao, M. N., Lloyd, N., Wong, R. K., Chow, E., Rakovitch, E., Laperriere, N., Xu, W., & Sahgal, A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2012-04-18
- Volume
- 1
- Issue
- 4
- Pages
- CD003869-CD003869
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2107529266
- Cited by
- 399
- References
- 51
- FWCI
- 24.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.